These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
461 related items for PubMed ID: 16183330
1. Strontium as therapy for osteoporosis. Marie PJ. Curr Opin Pharmacol; 2005 Dec; 5(6):633-6. PubMed ID: 16183330 [Abstract] [Full Text] [Related]
2. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation. Marie PJ. Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S11-5. PubMed ID: 16735840 [Abstract] [Full Text] [Related]
4. Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bonnelye E, Chabadel A, Saltel F, Jurdic P. Bone; 2008 Jan; 42(1):129-38. PubMed ID: 17945546 [Abstract] [Full Text] [Related]
7. [Strontium Ranelate as a new therapeutic agent for osteoporosis]. Imanishi Y, Nishizawa Y. Clin Calcium; 2005 Jan; 15(1):25-8. PubMed ID: 15632469 [Abstract] [Full Text] [Related]
9. Strontium ranelate: an increased bone quality leading to vertebral antifracture efficacy at all stages. Ortolani S, Vai S. Bone; 2006 Feb; 38(2 Suppl 1):19-22. PubMed ID: 16455319 [Abstract] [Full Text] [Related]
10. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. Roux C, Reginster JY, Fechtenbaum J, Kolta S, Sawicki A, Tulassay Z, Luisetto G, Padrino JM, Doyle D, Prince R, Fardellone P, Sorensen OH, Meunier PJ. J Bone Miner Res; 2006 Apr; 21(4):536-42. PubMed ID: 16598373 [Abstract] [Full Text] [Related]
11. Improvement in bone strength parameters. The role of strontium ranelate. Tournis S. J Musculoskelet Neuronal Interact; 2007 Apr; 7(3):266-7. PubMed ID: 17947810 [Abstract] [Full Text] [Related]
15. Strontium ranelate in the prevention of osteoporotic fractures. Reginster JY, Malaise O, Neuprez A, Bruyere O. Int J Clin Pract; 2007 Feb; 61(2):324-8. PubMed ID: 17263720 [Abstract] [Full Text] [Related]
16. Protelos: nonvertebral and hip antifracture efficacy in postmenopausal osteoporosis. Adami S. Bone; 2006 Feb; 38(2 Suppl 1):23-7. PubMed ID: 16434247 [Abstract] [Full Text] [Related]
17. Strontium ranelate: the first agent of a new therapeutic class in osteoporosis. Neuprez A, Hiligsmann M, Scholtissen S, Bruyere O, Reginster JY. Adv Ther; 2008 Dec; 25(12):1235-56. PubMed ID: 19066755 [Abstract] [Full Text] [Related]
18. Strontium ranelate: a physiological approach for an improved bone quality. Ammann P. Bone; 2006 Feb; 38(2 Suppl 1):15-8. PubMed ID: 16455318 [Abstract] [Full Text] [Related]
19. [Therapeutic agents for disorders of bone and calcium metabolism. Osteoporotic fracture prevention by strontium ranelate]. Nakamura T. Clin Calcium; 2007 Jan; 17(1):80-7. PubMed ID: 17211097 [Abstract] [Full Text] [Related]
20. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Reginster JY, Felsenberg D, Boonen S, Diez-Perez A, Rizzoli R, Brandi ML, Spector TD, Brixen K, Goemaere S, Cormier C, Balogh A, Delmas PD, Meunier PJ. Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789 [Abstract] [Full Text] [Related] Page: [Next] [New Search]